AI Terminal
Convatec Group PLC
Share Issue/Capital Change • Dec 20, 2021
4959_rns_2021-12-20_7bc7760e-5d11-4cdb-8443-0c4cc4ac6415.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1759W
ConvaTec Group PLC
20 December 2021
ConvaTec Group Plc
Block Listing Application
Reading, United Kingdom - 20 December 2021
An application has been made to the Financial Conduct Authority and the London Stock Exchange for a block listing totalling 20,000,000 ordinary shares of 10 pence each ("Shares") to be admitted to the premium listing segment of the Official List of the FCA and to trading on the London Stock Exchange's main market for listed securities. When issued these Shares will rank pari passu with the existing ordinary shares.
These Shares are being reserved under a block listing and will be issued from time to time pursuant to the following scheme(s):
| Scheme | Number of Shares |
| ConvaTec Group Plc Long Term Incentive Plan | 9,850,000 |
| ConvaTec Group Plc US Employee Stock Purchase Plan | 290,000 |
| ConvaTec Group Plc Share Plan | 3,000,000 |
| ConvaTec Group Plc Deferred Bonus Plan | 430,000 |
| ConvaTec Group Plc UK SAYE | 1,830,000 |
| ConvaTec Group Plc Global SAYE Sub-Plan | 4,600,000 |
Admission of the Shares is expected on 21 December 2021.
Enquiries
Analysts and Investors
Kate Postans, VP Investor Relations, ConvaTec +44 (0)782 644 7807
Media
Buchanan: Chris Lane +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ALSFEASWSEFSELE